Prof. Li Long Jiang from China Sichuan University to share his clinical experience and success in “The Milestone of Recombinant human p53 Adenovirus First Gene Therapy in Cancer Treatment with focus in treatment of malignant head & neck tumors”, followed by a renowned oncologist from Hong Kong, Dr. Wesely Shiu to speak on " Gendicine® - a paradigm shift in cancer management". Both speakers complimented each other in their experiences and cancer patient care management using Gendicine® for the treatment regiment from head and neck to other commonly seen cancers as having the lesions in the breast, lung, liver, pancreas, colon and sarcoma. The technique included Gendicine® direct Injection under ultrasonic guidance, Gendicine® +Avastin with Hyperthermia and artery perfusion applications.

Our visitors from Middle East countries are all head and neck specialists. They were so impressed on the Gendicine® efficacy for the treatment in malignant solid tumors that they have decided to work on developing the Gendicine ® compassionate program in their countries.